Zobrazeno 91 - 100
of 199
pro vyhledávání: '"Nina D. Wagner-Johnston"'
Autor:
Sanatan Shreay, Ian W. Flinn, Andreas Viardot, Yeonhee Kim, Matthias Will, Peter Martin, Gilles Salles, Madlaina Breuleux, Stephen J. Schuster, Bess Sorensen, Wojciech Jurczak, Nina D. Wagner-Johnston, Christopher R. Flowers, Kristie A. Blum, Brad S. Kahl, Sven de Vos, Ajay K. Gopal, Pier Luigi Zinzani
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.e156-e159. ⟨10.3324/haematol.2016.151738⟩
Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.e156-e159. ⟨10.3324/haematol.2016.151738⟩
Approximately 20% of all non-Hodgkin lymphoma (NHL) and 60% of indolent NHL (iNHL) cases are follicular lymphoma (FL),[1][1],[2][2] a disease considered treatable, but not curable, with currently available therapeutic options.[3][3] While survival in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506e68755679b39063547218b4074798
https://ruj.uj.edu.pl/xmlui/handle/item/103231
https://ruj.uj.edu.pl/xmlui/handle/item/103231
Autor:
Jennifer R. Brown, Ian W. Flinn, Stephen E. Spurgeon, Steven Coutre, Yoonjin Cho, John C. Byrd, Richard R. Furman, Wayne R. Godfrey, Don M. Benson, Brad S. Kahl, Nina D. Wagner-Johnston, Albert S. Yu, Sissy Peterman
Publikováno v:
Blood. 123:3398-3405
Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was sa
Autor:
Alison J. Moskowitz, Oliver Sartor, Charles L. Bennett, Alain H. Rook, Thomas Coyne, Gloria von Geldern, Craig H. Moskowitz, Ellen J. Kim, Alison W. Loren, Dennis W. Raisch, Scott D. Newsome, LeAnn B. Norris, Donald E. Tsai, Nina D. Wagner-Johnston, Kenneth R. Carson, Daniel J. Landsburg, P. Brandon Bookstaver, Pankaj Jalan
Publikováno v:
Cancer. 120:2464-2471
Purpose Brentuxiumab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate approved in 2011 for treating anaplastic large cell and Hodgkin lymphomas. The product label indicates that three BV-treated patients developed progressive multifoca
Autor:
Julie M. Vose, Daniel Eastwood, Martin Bast, Timothy S. Fenske, Jonathan Thompson, Luiza Havlat, Sai Ravi Pingali, Nina D. Wagner-Johnston, Sarah Jewell, Nancy L. Bartlett, James O. Armitage
Publikováno v:
Cancer. 120:2122-2129
BACKGROUND The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imagin
Autor:
Guan Xing, Jeffrey A. Jones, Xavier Badoux, Farrukh T. Awan, Carolyn Owen, Kerry Taylor, Loic Ysebaert, Ian W. Flinn, Javier Loscertales, Elisabeth Vandenberghe, Lyndah Dreiling, Malgorzata Wach, Nina D. Wagner-Johnston, Tadeusz Robak, Steven Coutre, Jennifer R. Brown, Ronald L. Dubowy
Publikováno v:
The Lancet. Haematology. 4(3)
Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituximab. We aimed to assess the efficacy and safety of idelalisib in combination with a sec
Autor:
Thaddeus J. Unger, Nashat Y. Gabrail, Martin Gutierrez, Rachid Baz, Boris Klebanov, Tami Rashal, Sharon Shacham, Robert W. Carlson, Ramiro Garzon, Richard Stone, Karen W.L. Yee, Michael Andreeff, Trinayan Kashyap, Paul Morten Mau-Sorensen, Michael R. Savona, Nina D. Wagner-Johnston, Michael Kauffman, Jean Richard Saint-Martin, Lynn Savoie
Publikováno v:
Blood
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study
Autor:
D. Mahadevan, J.M. Pagel, H. Quach, A. Mohrbacher, W. Rybka, P. Walker, J. Gwo, Francisco J. Hernandez-Ilizaliturri, Gareth P. Gregory, Stephen Opat, D. Wang, Julie E. Chang, Nina D. Wagner-Johnston, H. Ma, M. Farooqui, Andreas K. Klein, C. Escobar, Jake Shortt
Publikováno v:
HemaSphere. 3:487
Autor:
Danna Chan, Francine M. Foss, Monica M. Mita, Roberta Ferraldeschi, Felipe Samaniego, John Lister, Amitkumar Mehta, Martin J. S. Dyer, Anca Prica, Antoine Hollebecque, F. Hernandez-Llizaliturri, Nina D. Wagner-Johnston, B. You, J. Zhang
Publikováno v:
HemaSphere. 3:486
Autor:
B. You, J. Zhang, Anca Prica, Francine M. Foss, Antoine Hollebecque, Danna Chan, Roberta Ferraldeschi, F. Hernandez-Llizaliturri, John Lister, Martin J. S. Dyer, Amitkumar Mehta, Monica M. Mita, Nina D. Wagner-Johnston, Felipe Samaniego
Publikováno v:
Hematological Oncology. 37:527-527
Autor:
Brian A. Costello, Costantine Albany, Sara I Edwards, Eric G. Wolfe, Nina D. Wagner-Johnston, Lina M Sego, Kayla Marie Lazzara, Deirdre R. Pachman, Christin I. Snow, Charles L. Loprinzi, Travis J. Dockter, Nasser H. Hanna, Lawrence H. Einhorn
Publikováno v:
Journal of Clinical Oncology. 37:e23078-e23078
e23078 Background: There are limited patient (pt) reported outcome data regarding CDDP neurotoxicity. Methods: CDDP-induced peripheral neuropathy was evaluated in pts with testicular cancer planning to receive CDDP (20 mg/m2/d for 5 days) for ≥ 3 c